<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/92267032-BF6D-4396-8AB2-058B89D0964A"><gtr:id>92267032-BF6D-4396-8AB2-058B89D0964A</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:surname>Butter</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/20FE5C39-BD7C-4993-A28B-5EEAAF8E46BE"><gtr:id>20FE5C39-BD7C-4993-A28B-5EEAAF8E46BE</gtr:id><gtr:firstName>Amy</gtr:firstName><gtr:surname>Boyd</gtr:surname><gtr:orcidId>0000-0002-8250-5488</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FI%2F00001482"><gtr:id>17F41C23-42DD-4310-B27A-C8EE8AF28D71</gtr:id><gtr:title>IAH Jenner Fellowship: Assessing the efficacy of recombinant viral vaccines to induce heterosubtypic immunity to influenza in birds</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/I/00001482</gtr:grantReference><gtr:abstractText>Existing seasonal flu vaccines target the highly variable haemagglutinin (HA) surface protein. While effective, these vaccines must be administered annually and provide little if any heterosubtypic immunity. Cytotoxic T lymphocytes (CTL) targeting conserved internal antigens of influenza have been shown to mediate a cross-protective response. The Jenner Institute is currently testing Adenovirus and Modified Vaccinia Virus Ankara (MVA) encoding the internal influenza antigens NP and M1 in humans. These vaccines are designed to boost pre-existing CTL responses in adults, and through prime boost regimes may help to provide heterosubtypic immunity in infants, who unlike most adults have not been repeatedly exposed to influenza. The Jenner-IAH fellowship is part of the Jenner Institute?s One Health approach to vaccine development, developing vaccines for humans and animals in parallel. The main aim of the fellowship is to assess the efficacy of these recombinant viral vaccines in chickens, to determine if boosting CTL responses to internal antigens will induce heterosubtypic immunity in birds.</gtr:abstractText><gtr:fund><gtr:end>2012-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2010-02-08</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>220845</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>I demonstrated that the MVA-adenovirus prime boost system utilized by the Jenner Institute is effective in reducing shedding of virus during avian influenza infection.</gtr:description><gtr:exploitationPathways>Further antigens could be tested using this system to enhance efficacy. Protection against high pathogenic flu infection could be tested. Routes of administration could be tested to make these vaccines useable in commercial settings.</gtr:exploitationPathways><gtr:id>E822A2F7-D463-4EAE-9F35-F678A8D1EE5E</gtr:id><gtr:outcomeId>59197a88c85611.88454969</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Environment,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>86CEE928-3DB6-474A-A26D-544971778DB5</gtr:id><gtr:title>Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b8514ec0b79e0b031c1f237095a2e61"><gtr:id>1b8514ec0b79e0b031c1f237095a2e61</gtr:id><gtr:otherNames>Boyd AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>591977d7828140.39001637</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3ECC402B-CD94-4A2F-B7BB-B2F61A0AA156</gtr:id><gtr:title>Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a3c8292cef014ea5081874f71d6f03f"><gtr:id>5a3c8292cef014ea5081874f71d6f03f</gtr:id><gtr:otherNames>Mullarkey CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>591977d7435ab4.37924638</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/I/00001482</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>